Article
Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial.
Antiviral therapy - 1 Jan 2011
Manns Michael, Reesink Henk, Berg Thomas, Dusheiko Geoffrey, Flisiak Robert, Marcellin Patrick, Moreno Christophe, Lenz Oliver, Meyvisch Paul, Peeters Monika, Sekar Vanitha, Simmen Kenneth, Verloes Rene
Abstract excerpt
BACKGROUND: Antiviral activity of TMC435, an oral, once-daily, HCV NS3/4A protease inhibitor, was evaluated with pegylated interferon-α2a/ribavirin (P/R) in HCV genotype-1 patients. METHODS: Optimal Protease inhibitor Enhancement of Response to TherApy (OPERA-1; TMC435-C201; NCT00561353) is a Phase IIa, randomized, placebo-controlled study. Treatment-naive patients (n=74) received 25, 75 or 200 mg TMC435 once...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.